為應(yīng)對未來的冠狀病毒威脅而開發(fā)的新型多合一疫苗
指南者留學(xué)
2022-07-06 11:14:14
閱讀量：1245
<div data-page-id="doxcnG10oM3yctCBUXfZqRgjQ7d" data-docx-has-block-data="true">
<div class="image-uploaded gallery old-record-id-doxcn6KOk66QK8YEKE3U5LvHgBf" style="text-align: justify;" data-type="image" data-ace-gallery-json="{"items":[{"uuid":"e4658f7c-18ac-4e9d-ac9d-55f2452a550b","height":575,"width":1200,"currHeight":575,"currWidth":1200,"natrualHeight":575,"natrualWidth":1200,"pluginName":"imageUpload","scale":1,"src":"https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2FboxcnmJa2RS5LBdK4YJ0DedgPmc%2F%3Fmount_node_token%3Ddoxcn6KOk66QK8YEKE3U5LvHgBf%26mount_point%3Ddocx_image","file_token":"boxcnmJa2RS5LBdK4YJ0DedgPmc","image_type":"image/png","size":848157,"comments":[]}]}">
<div data-page-id="doxcnG10oM3yctCBUXfZqRgjQ7d" data-docx-has-block-data="true">
<div class="image-uploaded gallery old-record-id-doxcn6KOk66QK8YEKE3U5LvHgBf" style="text-align: justify;" data-type="image" data-ace-gallery-json="{"items":[{"uuid":"0d1380e4-5eb0-4b5a-9bb9-58e935b784e8","height":575,"width":1200,"currHeight":575,"currWidth":1200,"natrualHeight":575,"natrualWidth":1200,"pluginName":"imageUpload","scale":1,"src":"https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2FboxcnmJa2RS5LBdK4YJ0DedgPmc%2F%3Fmount_node_token%3Ddoxcn6KOk66QK8YEKE3U5LvHgBf%26mount_point%3Ddocx_image","file_token":"boxcnmJa2RS5LBdK4YJ0DedgPmc","image_type":"image/png","size":848157,"comments":[]}]}"><img src="https://info.compassedu.hk/sucai/content/1657534657105/1657534657105.png" width="807" height="387" /></div>
</div>
</div>
<h2 class="heading-2 ace-line old-record-id-doxcnOkekSAkmsmm8iEhxVGFKIc" style="text-align: justify;"><strong><span class="p">流行病防范創(chuàng)新聯(lián)盟（CEPI）已宣布提供高達(dá)3000萬美元的資金，將一種新型納米顆粒疫苗用于臨床試驗(yàn)，以提供對一系列冠狀病毒的保護(hù)。</span></strong></h2>
<p style="text-align: justify;"> </p>
<div class="ace-line ace-line old-record-id-doxcnMuYKekYCCmM4x12Tm2agGu" style="text-align: justify;">截至2022年7月，隨著SARS-CoV-2浪潮的不斷涌現(xiàn)，不確定性仍然存在。隨著時(shí)間的推移，新的病毒變種出現(xiàn)，并有可能減少現(xiàn)有疫苗工作的影響。顯然需要制定戰(zhàn)略，既要應(yīng)對新出現(xiàn)的變種，又要保護(hù)人群免受未來對人類健康的潛在威脅，例如相關(guān)的蝙蝠病毒。</div>
<div class="ace-line ace-line old-record-id-doxcnMuYKekYCCmM4x12Tm2agGu" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcn22QEmQM8QOgiaovi3RGszd" style="text-align: justify;"><a href="https://www.uk-cpi.com/news/cepi-funds-consortium-led-by-cpi-to-advance-caltechs-new-all-in-one-coronavirus-vaccine" target="_blank" rel="noopener">一個(gè)新的聯(lián)盟旨在通過為新的疫苗設(shè)計(jì)建立第一個(gè)人體臨床概念驗(yàn)證來解決這些問題。</a>該疫苗將針對SARS-CoV-2和一些有可能傳播給人類的相關(guān)蝙蝠病毒。它建立在牛津大學(xué)分子免疫學(xué)小組和加州理工學(xué)院比約克曼小組開發(fā)的技術(shù)之上 - 分別由MRC人體免疫學(xué)部門的<a href="https://www.rdm.ox.ac.uk/people/alain-townsend" target="_blank" rel="noopener">Alain Townsend教授</a>和Pamela Bjorkman教授領(lǐng)導(dǎo)。</div>
<div class="image-uploaded gallery old-record-id-doxcnWo0IYCuuCq0KGhaYxrYxeb" style="text-align: justify;" data-type="image" data-ace-gallery-json="{"items":[{"uuid":"cd1fd9ed-40ca-4982-bf25-0a932b78bed3","height":239.66480446927372,"width":194.99999999999997,"currHeight":239.66480446927372,"currWidth":194.99999999999997,"natrualHeight":220,"natrualWidth":179,"pluginName":"imageUpload","scale":1.089385474860335,"src":"https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2Fboxcn5E6JQuBamt3idLFEoVcQ5y%2F%3Fmount_node_token%3DdoxcnWo0IYCuuCq0KGhaYxrYxeb%26mount_point%3Ddocx_image","file_token":"boxcn5E6JQuBamt3idLFEoVcQ5y","image_type":"image/jpeg","size":10029,"comments":[]}]}">
<div data-page-id="doxcnG10oM3yctCBUXfZqRgjQ7d" data-docx-has-block-data="true">
<div class="image-uploaded gallery old-record-id-doxcnWo0IYCuuCq0KGhaYxrYxeb" data-type="image" data-ace-gallery-json="{"items":[{"uuid":"0d54023d-855d-4eec-9f3e-70e1cc7ef06d","height":239.66480446927372,"width":194.99999999999997,"currHeight":239.66480446927372,"currWidth":194.99999999999997,"natrualHeight":220,"natrualWidth":179,"pluginName":"imageUpload","scale":1.089385474860335,"src":"https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2Fboxcn5E6JQuBamt3idLFEoVcQ5y%2F%3Fmount_node_token%3DdoxcnWo0IYCuuCq0KGhaYxrYxeb%26mount_point%3Ddocx_image","file_token":"boxcn5E6JQuBamt3idLFEoVcQ5y","image_type":"image/jpeg","size":10029,"comments":[]}]}"><img style="display: block; margin-left: auto; margin-right: auto;" src="https://info.compassedu.hk/sucai/content/1657534662469/1657534662469.jpg" width="179" height="220" /></div>
</div>
</div>
<div class="ace-line ace-line old-record-id-doxcn42WWec28U8gEVe0lssBRcI" style="text-align: justify;">該聯(lián)盟匯集了牛津大學(xué)和加州理工學(xué)院的研究人員，與深度技術(shù)創(chuàng)新組織CPI和工業(yè)生物技術(shù)公司Ingenza Ltd（Caltech-CPI-Oxford-Ingenza）合作。</div>
<div class="ace-line ace-line old-record-id-doxcn42WWec28U8gEVe0lssBRcI" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnG4wwSwSSQs2GCQoelUcjnt" style="text-align: justify;">流行病防范創(chuàng)新聯(lián)盟（CEPI）將與該聯(lián)盟合作，并宣布提供高達(dá)3000萬美元的資金，用于資助基于該技術(shù)的臨床前研究，GMP制造和1期試驗(yàn)。</div>
<div class="ace-line ace-line old-record-id-doxcnG4wwSwSSQs2GCQoelUcjnt" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnWy0gYQEuWSMgOmu0QgLbYf" style="text-align: justify;">與許多使用mRNA或病毒載體將單一類型病毒的刺突蛋白片段呈現(xiàn)給免疫系統(tǒng)的現(xiàn)有疫苗設(shè)計(jì)相反，這種新疫苗將使用含有蛋白質(zhì)“膠水”的蛋白質(zhì)納米顆粒來附著來自八種不同病毒的刺突蛋白的相關(guān)抗原切片。通過結(jié)合加州理工學(xué)院創(chuàng)建的“mosaic-8疫苗”設(shè)計(jì)，這些納米顆粒將有利于對單一疫苗中每種不同類型的冠狀病毒的共享部分的免疫反應(yīng)。</div>
<div class="ace-line ace-line old-record-id-doxcnWy0gYQEuWSMgOmu0QgLbYf" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcn2K8w0gKuWuq2kjuLg0TiBf" style="text-align: justify;">研究人員今天發(fā)表在《<em><a href="https://www.science.org/doi/10.1126/science.abq0839" target="_blank" rel="noopener">科學(xué)》雜志</a></em>上的證據(jù)顯示，這種疫苗技術(shù)不僅可以引發(fā)針對SARS樣病毒的保護(hù)性免疫反應(yīng)，還可以針對試驗(yàn)疫苗中未出現(xiàn)的一些冠狀病毒。這表明該技術(shù)可以提供保護(hù)，防止未來新的SARS-CoV-2變體和尚未發(fā)現(xiàn)的冠狀病毒，這些冠狀病毒有可能從動(dòng)物種群中溢出。</div>
<div class="ace-line ace-line old-record-id-doxcn2K8w0gKuWuq2kjuLg0TiBf" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnA4KKsYqOeskqsFvCMTcHsb" style="text-align: justify;">該聯(lián)盟的牛津負(fù)責(zé)人，牛津大學(xué)MRC Weatherall分子醫(yī)學(xué)研究所分子免疫學(xué)教授Alain Townsend說：</div>
<div class="ace-line ace-line old-record-id-doxcnOAw8kg0cmeucczM7beBOeh" style="text-align: justify;">“這個(gè)聯(lián)盟的演變是合作科學(xué)最好的一個(gè)例子。馬克·豪沃思（Mark Howarth）（牛津大學(xué)生物化學(xué)）開發(fā)的將蛋白質(zhì)粘在一起的“膠水”的力量給我們留下了深刻的印象，這種“膠水”來自他對<em>化膿性鏈球菌</em>細(xì)菌的美麗基礎(chǔ)科學(xué)研究。</div>
<div class="ace-line ace-line old-record-id-doxcnOAw8kg0cmeucczM7beBOeh" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcn6sEMs2egOYQ8cF99h7RpOe" style="text-align: justify;">“我們一起使用這項(xiàng)技術(shù)制造了一種原型納米顆粒SARS-CoV-2疫苗，該疫苗在臨床前研究中誘導(dǎo)了有效的反應(yīng)。</div>
<div class="ace-line ace-line old-record-id-doxcn6sEMs2egOYQ8cF99h7RpOe" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcni0GWG0YuQOmO47BYfhK2Pg" style="text-align: justify;">“通過Ian Wilkinson（絕對抗體）建立的聯(lián)系，我們與Ingenza和CPI的同事一起成功制造了微生物中生產(chǎn)的疫苗的全功能版本，從而降低了生產(chǎn)成本。我們一直在與Pamela Bjorkman教授和加州理工學(xué)院團(tuán)隊(duì)合作，他們獨(dú)立開發(fā)了馬賽克疫苗版本的精彩概念，并很高興繼續(xù)與這個(gè)世界級(jí)的聯(lián)盟合作。</div>
<div class="ace-line ace-line old-record-id-doxcni0GWG0YuQOmO47BYfhK2Pg" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcne2mAikuy8g62cfFrFZpidc" style="text-align: justify;">財(cái)團(tuán)合作伙伴致力于實(shí)現(xiàn)公平獲得項(xiàng)目產(chǎn)出。</div>
<div class="ace-line ace-line old-record-id-doxcne2mAikuy8g62cfFrFZpidc" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnyCQQWsMGs60IOQNOSy70Pe" style="text-align: justify;">該聯(lián)盟的項(xiàng)目經(jīng)理（牛津大學(xué)），MRC Weatherall分子醫(yī)學(xué)研究所的高級(jí)博士后科學(xué)家<a href="https://www.rdm.ox.ac.uk/people/tiong-tan" target="_blank" rel="noopener">Jack Tan博士</a>說：</div>
<div class="ace-line ace-line old-record-id-doxcn2egEWWumQMqyqgFAOVN6bd" style="text-align: justify;">“我們很高興與CEPI合作，進(jìn)一步推進(jìn)這種納米顆粒技術(shù)，目標(biāo)是生產(chǎn)有效，低成本，基礎(chǔ)設(shè)施獨(dú)立的疫苗，這些疫苗將可供低收入和中等收入國家使用。</div>
<div class="ace-line ace-line old-record-id-doxcn2egEWWumQMqyqgFAOVN6bd" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnQwSEK88iCcOwGYuaAcOqIb" style="text-align: justify;">CEPI首席執(zhí)行官Richard Hatchett博士說：“21世紀(jì)已經(jīng)發(fā)生了三次嚴(yán)重的冠狀病毒流行病或大流行 - COVID-19繼續(xù)對世界的健康，社會(huì)和經(jīng)濟(jì)產(chǎn)生破壞性影響。創(chuàng)造能夠針對新出現(xiàn)的COVID-19變種和未來冠狀病毒威脅提供廣泛保護(hù)的疫苗不僅有助于減輕另一種類似COVID-19的大流行的破壞性影響，還有助于減少不斷更新疫苗配方所花費(fèi)的時(shí)間和資金。</div>
<div class="ace-line ace-line old-record-id-doxcnQwSEK88iCcOwGYuaAcOqIb" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnmaigg8IQ88ISocb3Wdvip6" style="text-align: justify;">“這就是為什么我們很高興今天與這個(gè)由CPI領(lǐng)導(dǎo)的研究聯(lián)盟合作，以Wellcome Leap的初始投資為基礎(chǔ)，進(jìn)一步推進(jìn)這種開創(chuàng)性的馬賽克納米顆粒疫苗技術(shù)，如果成功，可以致力于將冠狀病毒構(gòu)成的威脅托付給歷史書。</div>
<div class="ace-line ace-line old-record-id-doxcnmaigg8IQ88ISocb3Wdvip6" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcne0kC6ugKyIqCu6YHx6zzmd" style="text-align: justify;">該聯(lián)盟的目標(biāo)是在2024年開始由牛津疫苗集團(tuán)領(lǐng)導(dǎo)的1期試驗(yàn)。</div>
</div>
預(yù)約咨詢
預(yù)約咨詢
猜你喜歡
七日熱點(diǎn)資訊
微信咨詢
掃一掃立即咨詢
App下載
下載指南者留學(xué)App
預(yù)約咨詢
電話咨詢
400-183-1832
回到頂部
預(yù)約咨詢
登錄
二維碼已過期
重新獲取
已掃碼
等待確認(rèn)登錄
請使用微信掃描二維碼登錄